Castle Biosciences (CSTL) Total Liabilities (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Total Liabilities data on file, last reported at $86.4 million in Q1 2026.

• Quarterly Total Liabilities rose 40.68% year-over-year to $86.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $86.4 million (up 40.68% YoY) and the FY2025 annual result came in at $107.7 million, up 42.82% from the prior year.
• Total Liabilities slipped to $86.4 million in Q1 2026 per CSTL's latest filing, from $107.7 million in the prior quarter.
• The five-year high for Total Liabilities was $107.7 million in Q4 2025, with the low at $36.7 million in Q2 2022.
• Average Total Liabilities over 5 years is $64.0 million, with a median of $61.4 million recorded in 2025.
• Year-over-year, Total Liabilities jumped 151.21% in 2022 and declined 11.36% in 2023.
• Castle Biosciences' Total Liabilities stood at $48.2 million in 2022, then advanced by 28.83% to $62.1 million in 2023, then advanced by 21.47% to $75.4 million in 2024, then soared by 42.82% to $107.7 million in 2025, then retreated by 19.77% to $86.4 million in 2026.
• Business Quant data shows CSTL's Total Liabilities at $86.4 million in Q1 2026, $107.7 million in Q4 2025, and $95.7 million in Q3 2025.